The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Grading Ovarian Serous Carcinoma Using a Two-Tier System
Abstract
In this study, we evaluate a two-tier system for grading ovarian serous carcinoma. This system is based primarily on the assessment of nuclear atypia with the mitotic rate used as a secondary feature. The study included 50 cases of low-grade ovarian serous carcinoma and 50 cases of high-grade ovarian serous carcinoma retrieved from the files of the Department of Pathology at the University of Texas M. D. Anderson Cancer Center from a 28-year period. Cases assigned to the low-grade category were characterized by the presence of mild to moderate nuclear atypia. As a secondary feature, they tended to show up to 12 mitoses per 10 high power fields (HPFs), whereas those in the high-grade category had marked nuclear atypia and as a secondary feature more than 12 mitoses per 10 HPFs. For comparison, the tumors were also graded using the Shimizu/Silverberg and the FIGO grading systems. Patients in the low-grade ovarian serous carcinoma group ranged in age from 19 to 75 years (mean 41.7 years) while patients in the high-grade ovarian serous carcinoma group ranged in age from 27 to 76 years (mean 55 years). All of the cases except one were advanced FIGO stage. Using the Shimizu/Silverberg system, the low-grade ovarian serous carcinoma cases were distributed as follows: grade 1, 47 cases; grade 2, 3 cases. Using the FIGO grading system, 35 cases were grade 1 and 15 cases were grade 2. Regarding the high-grade ovarian serous carcinoma group using the Shimizu/Silverberg system, 14 of the cases were grade 2 and 36 cases were grade 3. Using the FIGO grading system, 1 case was grade 1, 38 cases were grade 2, and 11 cases were grade 3. Most of the patients in both groups were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy and also received cisplatinum-based chemotherapy. On follow-up, 37 patients in the low-grade ovarian serous carcinoma group had died of disease at a median 4.2 years after diagnosis compared with 46 patients in the high-grade ovarian serous carcinoma group who died of disease at a median of 1.7 years. Eight patients in the low-grade ovarian serous carcinoma group and 4 patients in the high-grade ovarian serous carcinoma group were alive with disease at median follow-ups of 4.3 and 3.85 years, respectively. Four patients with low-grade serous carcinoma were alive without evidence of disease after a follow-up that ranged from 4.4 to 22.6 years (median 6.85 years), and one died of other causes 14 years after the diagnosis of her ovarian tumor. On multivariate analysis, residual tumor and tumor grade based on the M. D. Anderson two-tier system for grading ovarian serous carcinoma were found to be significant independent prognostic factors (P = 0.003 and 0.04, respectively). Of interest, 60% of the low-grade ovarian serous carcinomas in this study were associated with a serous neoplasm of low malignant potential, whereas this association was present in only 2% of the high-grade ovarian serous carcinomas. This finding could reflect a difference in the pathogenesis of ovarian serous carcinomas of different grades. In summary, there is usually a good correlation between the two-tier grading system herein presented and the Shimizu/Silverberg and the FIGO grading systems. Because this system is based on defined criteria that are easy to follow and because it involves only two diagnostic categories, it should provide better reproducibility in the grading of ovarian serous carcinoma. However, additional studies are required to validate these statements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histopathologic Grading of Ovarian Carcinoma: A Review and Proposal
Silverberg, S. G. (2000) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200001000-00003 · Cited by 351
Studies on Bilirubin in Amniotic Fluid: With Special Reference to Liver Function Tests
Ojala, A. (1971) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.3109/00016347109157182 · Cited by 271
Shimizu, Y., Kamoi, S., Amada, S., Akiyama, F., & Silverberg, S. G. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980301)82:5<893::aid-cncr14>3.0.co;2-w · Cited by 254
p53 Mutations and Expression in Ovarian Cancers: Correlation with Overall Survival
Wen, W., Reles, A., Runnebaum, I. B., Sullivan‐Halley, J., Bernstein, L., Jones, L. A., Felix, J. C., Kreienberg, R., El‐Naggar, A. K., & Press, M. F. (1999) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199901000-00005 · Cited by 143
Toward the Development of a Universal Grading System for Ovarian Epithelial Carcinoma
Shimizu, Y., Kamoi, S., Amada, S., et al. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5051 · Cited by 139
Eltabbakh, G. H., Belinson, J. L., KENNEDY, A. W., Biscotti, C. V., Casey, G., Tubbs, R. R., & Blumenson, L. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970901)80:5<892::aid-cncr10>3.0.co;2-r · Cited by 87
Ross, J. S., Yang, F., Kallakury, B., Sheehan, C. E., Ambros, R. A., & Muraca, P. J. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.3.311 · Cited by 72
Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study
Gadducci, A., Sartori, E., Maggino, T., Zola, P., Landoni, F., FANUCCHI, A., Stegher, C., Alessi, C., Buttitta, F., & E., T. B. (1997) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.1997.09742.x · Cited by 27
Cited by
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050232 · Cited by 814
Recent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
Cho, K. R., & Shih, I.-M. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092246 · Cited by 694
Prat, J. (2012) · Virchows Archiv · doi:10.1007/s00428-012-1203-5 · Cited by 602
Vang, R., Shih, I.-M., & Kurman, R. J. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181b4fffa · Cited by 562
Metadata
- Authors
- Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G.
- Venue
- The American Journal of Surgical Pathology
- Published
- 2004-04
- Volume
- 28
- Issue
- 4
- Pages
- 496-504
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W2055344345
- Cited by
- 670
- References
- 8
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Grading Ovarian Serous Carcinoma Using a Two-Tier System. https://app.cochat.ai/papers/10.1097/00000478-200404000-00009
- The paper
- Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004). Grading Ovarian Serous Carcinoma Using a Two-Tier System. The American Journal of Surgical Pathology. https://doi.org/10.1097/00000478-200404000-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.